Literature DB >> 24802769

Adaptive compression therapy for venous leg ulcers: a clinically effective, patient-centred approach.

Keith G Harding1, Wolfgang Vanscheidt2, Hugo Partsch3, Joseph A Caprini4,5, Anthony J Comerota6.   

Abstract

A prospective, randomised, 12-week study was performed to evaluate the efficacy and tolerability of two compression methods for venous leg ulcers (VLUs); a new adaptive compression therapy (ACT) system, combining intermittent and sustained pneumatic compression (n = 38) and a conventional four-layer bandage system (n = 52). Primary outcomes were ulcer healing and safety. Secondary outcomes were comfort, compliance, ulcer pain, patient-perceived product performance and quality of life. Ulcer healing rate was similar (31·6% versus 42·3%, respectively, P = 0·30) between the treatments. Adverse events and patient-rated comfort were also similar. Average daily usage for the dual system was 10·5 and 1·8 hours in the sustained and intermittent modes, respectively, representing its use during 71% of waking hours. Predicted final ulcer pain was also similar (P = 0·68). Performance was subjectively better for adaptive compression and significantly higher for exudate management (P = 0·04), skin protection (P < 0·001), removal ease (P = 0·0007), bathing (P < 0·0001) and sleep comfort (P = 0·0405). The adjusted final quality-of-life score was 0·1025 higher for adaptive compression (P = 0·0375). Subjects with healed ulcers attained higher final scores than unhealed subjects (P = 0·0004). This study provides evidence that ACT is comparably efficacious to successfully heal VLUs compared with four-layer bandage management but is better accepted and achieves higher patient-reported quality-of-life scores in these challenging patients.
© 2014 The Authors. International Wound Journal © 2014 Medicalhelplines.com Inc and John Wiley & Sons Ltd.

Entities:  

Keywords:  Adaptive compression therapy; Four-layer bandage; Pneumatic compression; Quality of life; Venous leg ulcer

Mesh:

Year:  2014        PMID: 24802769      PMCID: PMC7950102          DOI: 10.1111/iwj.12292

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  18 in total

1.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

2.  Predicting concordance with multilayer compression bandaging.

Authors:  C Miller; S Kapp; N Newall; G Lewin; K Carville; N Santamaria; L Karimi
Journal:  J Wound Care       Date:  2011-03       Impact factor: 2.072

3.  Randomized controlled trial comparing treatment outcome of two compression bandaging systems and standard care without compression in patients with venous leg ulcers.

Authors:  Irene K Y Wong; Anneke Andriessen; Diana T F Lee; David Thompson; Lau Yun Wong; David V K Chao; Winnie K W So; M Abel
Journal:  J Vasc Surg       Date:  2012-03-17       Impact factor: 4.268

4.  Efficacy of two compression systems in the management of VLUs: results of a European RCT.

Authors:  I Lazareth; C Moffatt; J Dissemond; A S Lesne Padieu; F Truchetet; S Beissert; G Wicks; H Tilbe; A Sauvadet; S Bohbot; S Meaume
Journal:  J Wound Care       Date:  2012-11       Impact factor: 2.072

Review 5.  Intermittent pneumatic compression for treating venous leg ulcers.

Authors:  E Andrea Nelson; Raj Mani; Kate Thomas; Kathryn Vowden
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

6.  VenUS I: a randomised controlled trial of two types of bandage for treating venous leg ulcers.

Authors:  C Iglesias; E A Nelson; N A Cullum; D J Torgerson
Journal:  Health Technol Assess       Date:  2004-07       Impact factor: 4.014

7.  Randomized trial of four-layer and two-layer bandage systems in the management of chronic venous ulceration.

Authors:  Christine J Moffatt; Lynn McCullagh; Theresa O'Connor; Debra C Doherty; Catherine Hourican; Julie Stevens; Trevor Mole; Peter J Franks
Journal:  Wound Repair Regen       Date:  2003 May-Jun       Impact factor: 3.617

8.  A randomised controlled 8-week crossover clinical evaluation of the 3M Coban 2 Layer Compression System versus Profore to evaluate the product performance in patients with venous leg ulcers.

Authors:  Christine J Moffatt; Lynfa Edwards; Mark Collier; Terry Treadwell; Michael Miller; Laura Shafer; Gary Sibbald; Alain Brassard; Andrea McIntosh; Alex Reyzelman; Patricia Price; Stacia Merkel Kraus; Shelley-Ann Walters; Keith Harding
Journal:  Int Wound J       Date:  2008-06       Impact factor: 3.315

Review 9.  Venous leg ulcers: patient concordance with compression therapy and its impact on healing and prevention of recurrence.

Authors:  Christine Moffatt; Dheerendra Kommala; Nathalie Dourdin; Yoonhee Choe
Journal:  Int Wound J       Date:  2009-10       Impact factor: 3.315

Review 10.  Compression for venous leg ulcers.

Authors:  Susan O'Meara; Nicky Cullum; E Andrea Nelson; Jo C Dumville
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14
View more
  4 in total

Review 1.  [New aspects of compression therapy].

Authors:  Bernhard Partsch; Hugo Partsch
Journal:  Wien Med Wochenschr       Date:  2016-06-03

2.  Assessment of the use of Unna boot in the treatment of chronic venous leg ulcers in adults: systematic review protocol.

Authors:  Thalita Paranhos; Caroline S B Paiva; Fernanda C I Cardoso; Priscila P Apolinário; Flavia Figueiredo Azevedo; Maria G B Saidel; Henrique C Oliveira; Ariane P Dini; Ana R S O Kumakura; Maria H Melo Lima
Journal:  BMJ Open       Date:  2019-12-23       Impact factor: 2.692

3.  Use of Sponge-Foam Inserts in Compression Bandaging of Non-Healing Venous Leg Ulcers.

Authors:  Rica Tanaka; Hideaki Inoue; Takeru Ishikawa; Yuichi Ichikawa; Rumiko Sato; Azusa Shimizu; Hiroshi Mizuno
Journal:  Ann Vasc Dis       Date:  2021-03-25

4.  Analysis of predicted full recovery time for venous leg ulcers treated with intermittent pneumatic compression.

Authors:  Paweł T Dolibog; Patrycja Dolibog; Daria Chmielewska
Journal:  Postepy Dermatol Alergol       Date:  2020-10-16       Impact factor: 1.837

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.